Riskpilot← Back to searchSign inGet full accessPHARMORE AS
ASActiveOrg 975989798Huvikveien 14, 3222 SandefjordBusiness and other management consultancy activities · NACE 7020Est. 19960 employees
Revenue 2024
NOK 463K
-48% vs 2023
EBITDA margin
45.0%
+91% vs 2023
Equity ratio
84.5%
Financial strength
Net profit 2024
NOK 26,7M
+1531% vs 2023
| Revenue | NOK 463K | -48% |
| EBITDA | NOK 208K | +91% |
| Net profit | NOK 26,7M | +1531% |
| Total assets | NOK 70,7M | +64% |
| Equity | NOK 59,7M | +81% |
| Employees | 0 | — |
Legal name
PHARMORE AS
Org number
975989798
Legal form
Aksjeselskap
NACE code
7020 · Business and other management consultancy activities
Founded
4. januar 1996
Share capital
NOK 528 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Å foreta investeringer i aksjer og verdipapirer, å drive handel med legemidler og andre varer, rådgivningsvirksomhet.
Address
Huvikveien 14, 3222 Sandefjord
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 464 | 1 836 | 1 611 | 597 | 651 | 347 | 235 | 120 | 120 | 712 | 975 | 796 | 883 | 853 | 344 | 890 | 463 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 795 | 1 082 | 953 | 279 | 329 | 148 | 206 | 72 | 67 | 211 | 383 | 315 | 162 | −21 | 70 | 109 | 208 |
| Depreciation & amort. | −0 | −0 | −0 | −3 | −3 | −3 | −3 | −3 | −0 | −68 | −124 | −219 | −219 | −224 | −115 | −171 | −70 |
| EBIT | 795 | 1 082 | 953 | 276 | 326 | 145 | 203 | 69 | 67 | 144 | 259 | 96 | −57 | −245 | −45 | −62 | 138 |
| Net financials | −1 793 | 297 | −20 | 51 | 510 | 7 122 | 6 072 | 10 358 | 264 | 21 405 | −233 | 18 627 | 9 085 | 16 699 | −1 338 | 1 685 | 26 589 |
| Profit before tax | −998 | 1 378 | 933 | 327 | 836 | 7 267 | 6 275 | 10 426 | 331 | 21 549 | 26 | 18 723 | 9 028 | 16 454 | −1 382 | 1 623 | 26 727 |
| Tax | 209 | 304 | 281 | 95 | 83 | 4 | 57 | 43 | 79 | −10 | 24 | −7 | −15 | −19 | 4 | −16 | 4 |
| Net profit | −1 206 | 1 075 | 652 | 231 | 753 | 7 264 | 6 218 | 10 383 | 252 | 21 559 | 2 | 18 730 | 9 043 | 16 473 | −1 386 | 1 639 | 26 724 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5 473 | 6 888 | 7 133 | 7 270 | 9 922 | 19 495 | 20 532 | 23 685 | 33 646 | 45 466 | 30 598 | 43 744 | 46 976 | 52 861 | 41 366 | 43 211 | 70 667 |
| Equity | 5 050 | 6 045 | 6 657 | 6 888 | 7 641 | 13 855 | 19 073 | 16 621 | 16 873 | 30 431 | 22 434 | 29 164 | 32 207 | 42 680 | 31 327 | 32 965 | 59 689 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 586 | 4 126 | 0 | 7 000 | 7 000 | 15 000 | 8 000 | 8 000 | 8 000 | 10 000 | 10 000 | 10 104 | 10 320 |
| Short-term debt | 423 | 844 | 476 | 383 | 695 | 1 515 | 1 459 | 64 | 9 774 | 34 | 164 | 6 580 | 6 769 | 181 | 40 | 142 | 658 |
| Total debt | 423 | 844 | 476 | 383 | 2 281 | 5 641 | 1 459 | 7 064 | 16 774 | 15 034 | 8 164 | 14 580 | 14 769 | 10 181 | 10 040 | 10 245 | 10 978 |
EBITDA margin
45.0%
This company
15.8%
Market median
+185% vs market
20082024
Equity ratio
84.5%
This company
38.2%
Market median
+121% vs market
20082024
Return on equity
44.8%
This company
18.4%
Market median
+143% vs market
20082024
Net profit margin
5771.5%
This company
8.1%
Market median
+71153% vs market
20082024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20082024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BK Deputy Member | Deputy Member | 2002 | — | — |
RS Chief Executive Officer | Chief Executive Officer | 2002 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMORE AS 
LØBBEDALEN 17 ASBoard members of PHARMORE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Berit Kårstad | Deputy Member | 0 companies |
| Ragnar Salmen | Chief Executive Officer | 0 companies |